• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

byStudy Graphics | C.WuandConstance Wu
September 6, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Religious-based interventions improve illness perception in breast cancer patients

Wellness Check: Spirituality

1. A randomized control trial of patients with hormone receptor-positive metastatic breast cancer compared survival outcomes between patients who received combined anastrozole and fulvestrant therapy versus those receiving anastrozole alone, concluded that the combined therapy led to improved disease progression-free survival and overall survival rates.

2. There were no significant differences found in grade 3 or higher toxic side effect rates between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Metastatic hormone-receptor positive breast cancer has long been associated with poor survival outcomes due to resistance to traditional therapies over time. In a breakthrough study first reported in NEJM in 2012, researchers from the S0226 trial indicated that such patients may derive some benefit from a combination therapy including anastrozole (an aromatase inhibitor) and fulvestrant (a selective estrogen receptor degrader). The initial results followed patients for a period of three years and found that the combined therapy led to increased overall survival rates and disease-free progressive survival rates when compared to a group of patients taking anastrozole alone.  This current analysis expands on those initial results, including five additional years of follow-up data. Researchers found that their overall survival and disease progression-free survival rates were still higher among patients who received the combined therapy. They also found that the safety profiles of each arm were not significantly different. This study strengthens the case for the use of combined therapy among patients with metastatic hormone-positive breast cancer.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anastrazoleBreast Cancerfulvestrant
Previous Post

Quick Take: Outcomes of Extremely Preterm Infants With Birth Weight Less Than 400 g

Next Post

#VisualAbstract: A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

RelatedReports

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Early palliative care may improve survival in advanced cancer
Wellness

Wellness Check: Spirituality

January 5, 2023
Oncology

Patients with HER2-positive advanced breast cancer and pathological complete response to neoadjuvant systemic therapy may not require surgical intervention

October 31, 2022
Next Post
#VisualAbstract: A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

#VisualAbstract: A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

UTI associated with increased risk of preeclampsia

Catheter-based renal denervation reduces blood pressure in patients with uncontrolled hypertension

Food environment associated with gestational diabetes

2 Minute Medicine Rewind April 8, 2019

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options